Last reviewed · How we verify
BAR502 single dose
At a glance
| Generic name | BAR502 single dose |
|---|---|
| Sponsor | BAR Pharmaceuticals s.r.l. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects (PHASE1)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAR502 single dose CI brief — competitive landscape report
- BAR502 single dose updates RSS · CI watch RSS
- BAR Pharmaceuticals s.r.l. portfolio CI